Prescription and Next-Generation Omega-3 Fatty Acids

Transcription

1 Prescription and Next-Generation Omega-3 Fatty Acids Event Type Live Online Expiration Date 2/10/2017 Credits 1 Contact Hour Target Audience Nurses, Pharmacists, Pharmacy Technicians Program Overview Recommendations by physicians and healthcare providers account for less than 25% of all dietary supplements consumed by American adults. Second in popularity to vitamins and calcium are fish oil supplements, despite consumer concerns regarding purity and proper dosing. The market for omega-3 fatty acids has expanded beyond OTC first-generation ethyl ester formulations and now includes prescription-only preparations, second-generation triglyceride forms, free fatty acid, phospholipid and krill oil formulations with various implications for therapeutic and metabolic effects, disease prevention and dosing. This webinar will explore these new formulations, indications for use beyond cardiovascular health, bioavailability concerns and will discuss differences between prescription formulations. Nurse/Pharmacist Educational Objectives To understand the differences between new prescription and over-the-counter forms of omega-3 fatty acids/marine oils that are currently available Offer insignts into established data and ongoing studies regarding omega-3 fatty acids in select non-cardiovascular condition To provide nurses greater options for informed patient counseling, safe use and education regarding dietary, dietary supplement, and prescription omega-3 fatty acid options Pharmacy Technician Educational Objectives List new omega-3 fatty acids/marine oils List benefits of taking omega-3 fatty acids/marine oils Activity Type Knowledge

2 Accreditation Nurse Pharmacist Pharmacy Technician N L01-P L01-T PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. PharmCon, Inc. has been approved as a provider of continuing education for nurses by the Maryland Nurses Association which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center s Commission on Accreditation. Faculty Matilde Parente, MD, FCAP Medical and Lifestyles Writer, Editopian Inc. Financial Support Received From Pharmaceutical Education Consultants, Inc. Disclaimer PharmCon, Inc. does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced and objective. Occasionally, authors may express opinions that represent their own viewpoint. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient or pharmacy management. Conclusions drawn by participants should be derived from objective analysis of scientific data presented from this activity and other unrelated sources.

3 PRESCRIPTION AND NEXT-GENERATION OMEGA-3 FATTY ACIDS ACTIVITY DESCRIPTION Recommendations by physicians and healthcare providers account for less than 25% of all dietary supplements consumed by American adults. Second in popularity to vitamins and calcium are fish oil supplements, despite consumer concerns regarding purity and proper dosing. The market for omega-3 fatty acids has expanded beyond OTC firstgeneration ethyl ester formulations and now includes prescription-only preparations, second-generation triglyceride forms, free fatty acid, phospholipid and krill oil formulations with various implications for therapeutic and metabolic effects, disease prevention and dosing. This webinar will explore these new formulations, indications for use beyond cardiovascular health, bioavailability concerns and will discuss differences between prescription formulations. TARGET AUDIENCE The target audience for this activity is pharmacists and pharmacy technicians in hospital, community, and retail pharmacy settings. LEARNING OBJECTIVES After completing this activity, the pharmacist will be able to: To understand the differences between new prescription and over-the-counter forms of omega-3 fatty acids/marine oils that are currently available Offer insights into established data and ongoing studies regarding omega-3 fatty acids in select non-cardiovascular condition To provide nurses greater options for informed patient counseling, safe use and education regarding dietary, dietary supplement, and prescription omega-3 fatty acid options ACCREDITATION PHARMACY PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NURSING PharmCon, Inc. is approved by the California Board of Registered Nursing (Provider Number CEP 13649) and the Florida Board of Nursing (Provider Number ). Activities approved by the CA BRN and the FL BN are accepted by most State Boards of Nursing. CE hours provided by PharmCon, Inc. meet the ANCC criteria for formally approved continuing education hours. The ACPE is listed by the AANP as an acceptable, accredited continuing education organization for applicants seeking renewal through continuing education credit. For additional information, please visit Universal Activity No H01-P&T Credits: 1 contact hour (0.1 CEU) Release Date: August 10, 2014 Expiration Date: August 10, 2017 ACTIVITY TYPE Knowledge-Based Home Study Webcast FINANCIAL SUPPORT BY Pharmaceutical Education Consultants, Inc. After completing this activity, the pharmacy technician will be able to: List new omega-3 fatty acids/marine oils List benefits of taking omega-3 fatty acids/marine oils 1

4 ABOUT THE AUTHOR Matilde Parente, MD is a California-based physician and medical safety consultant. She is a graduate of Duke University and the University of California, San Francisco School of Medicine. Dr. Parente is board certified in surgical and clinical pathology with postgraduate training in surgery, pathology and clinical experience in general practice and ambulatory care. She develops webinars for health professionals and is the author of articles for disease management, nutrition and wellness publications. Dr. Parente is an in-demand speaker and corporate trainer on topics related to workplace wellness, safety and women's health for business, professional and community groups. Matilde Parente, MD, FCAP FACULTY DISCLOSURE It is the policy of PharmCon, Inc. to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) and/or service(s) discussed in an educational activity. Matilde Parente reports no actual or potential conflict of interest in relation to this activity. Peer review of the material in this CE activity was conducted to assess and resolve potential conflict of interest. Reviewers unanimously found that the activity is fair balanced and lacks commercial bias. Please Note: PharmCon, Inc. does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced and objective. Occasionally, authors may express opinions that represent their own viewpoint. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient or pharmacy management. Conclusions drawn by participants should be derived from objective analysis of scientific data presented from this monograph and other unrelated sources. 2

5 3

6 4

7 5

8 6

9 7

10 8

11 9

12 10

13 11

14 12

15 13

16 14

17 15

18 ACTIVITY TEST 1. The first two FDA-approved prescription omega-3 fatty acids: A. Have a broad list of approved indications for dylipidemias B. Are both ethyl ester formulations C. Are an ethyl ester and a free fatty acid formulation D. Have been associated with unacceptable bleeding risks 2. Most omega-3 fatty acids available today: A. Are over-the-counter dietary supplements B. Are only available by prescription C. Contain unacceptable levels of dioxin contamination D. Contain unacceptable levels of mercury 3. Krill oil is manufactured from: A. Salmon B. Purified ethyl esters C. Small, shrimp-like crustaceans D. A mixture of finned oily fish 4. What percent of the US adult population use dietary supplements? A. Approximately 50% or more B. Less than 10% C. More than 90% D. Approximately 25% 5. Compared with EPA (eicosapentaenoic acid), which statement is true regarding DHA (docosahexaenoic acid)? A. It has been shown to be safer than EPA B. It is not an essential fatty acid C. It is the main fatty acid component in prescription icosapent ethyl D. It is more significantly associated with elevated LDL levels 16

19 6. At this juncture, which statement regarding omega-3 fatty acids and arthritis is most accurate? A. Omega-3 fatty acids have no proven benefit in arthritis of any type B. Benefits of omega-3 fatty acids in arthritis are a fish tale: No studies have been performed C. Omega-3 fatty acids have proven benefits in all types of arthritis D. Promising results have been demonstrated in clinical studies involving rheumatoid arthritis patients 7. Labeled, FDA-approved clinical indications for the use of prescription omega-3 fatty acids: A. Include all types of hyperlipidemias B. Are restricted to severe hypertriglyceridemia 500 mg/dl C. Are restricted to moderate ( mg/dl) and severe hypertriglyceridemia D. Are restricted to patients with LDL 100 mg/dl 8. The clinical pharmacology of omega-3 fatty acids includes all of the following except: A. Beneficial effects on cell membrane function B. Improvements in blood pressure and endothelial function C. Absence of a dose-response effect D. Beneficial effects on inflammation 9. Which of the following statements is not true regarding the presumptive triglyceridelowering actions of omega-3 fatty acids (O3 FA)? A. O3 FA enhance hepatic triglyceride clearance B. O3 FA work similarly to statins C. O3 FA decrease VLDL production D. O3 FA promote lipoprotein lipase (LpL) activity 10. Most over-the-counter fish oil preparations: A. Contain significant amounts of mercury B. Are biochemically the same as both prescription omega-3 preparations C. Show unpredictable dosage variability D. Contain more than the DRI of Vitamins A, D and E Please submit your final responses on freece.com. Thank you. 17